Study On The Correlations Of Visfatin And Polycystic Ovary Syndrome

Background and objective:The pathogenesis of PCOS has been unknown so far, but insulin resistance (IR) may be the pathological basis of PCOS. A growing number of studies have demonstrated that PCOS is a glycolipid metabolism disorder endocrine disease. Newly discovered in2005-visceral fat factor (visfatin), is a kind of fat factor closely related to glycolipid metabolism. This new finding pointed out the new direction of research and treatment to the pathogenesis of PCOS. By testing the serum visfatin levels in women of PCOS group and normal control group, we investigated the expression differences in polycystic ovary syndrome and normal people and analysis of related factors of visfatin among the different clinic phenotype of polycystic ovary syndrome, and we even further investigated the relationship between the serum visfatin levels and PCOS.Methods:66patients were recruited (October2010to December2011in Tianjin Medical University General Hospital) from the gynecologicail endocrine outpatient clinic and the center of Assisted reproductive who were diagnosed as PCOS as case group,30healthy volunteers or the ones who need the reproductive because of the factors of male factor or Blocked fallopian tubes as control group. All the subjects were excluded from other endocrinopathy and did not have any hormonal therapy for the past3months.All PCOS patients in the third-fifth day of menstrual cycle or without eggs whose diameter is greater than10mm development do the associated analytical review,test serum sex hormone six, do the insulin release test,and determine adrenocortical function. The control group’s level of hormones are measured. Seven fat samples’ are further tested on GLU, insulin and blood lipid, and the levels are normal.The samples menstrual cycle, height, weight, and so on are recorded.the66patients are divided into different groups according to the defferent levels of androgen, HOMA-IR,obesitas, dyslipidemia.And compare various groups within the clinical features, endocrine and visfatin levels. Results:1. The characteristic of clinic and endocrine and the different expression of visfatin between the PCOS and control group. PCOS group of average age (26.29±4.61); Menarche age (13.89±0.73); BMI (27.82±5.64kg/m2);66cases of patients with PCOS vaginal ultrasound examination were polycystic ovary,63.64%(42/66)cases with high androgen levels diagnosis, the incidence of menstruation disorder was87.88%(58/66),43cases of obesity, the incidence of obesity was65.15%(43/66);40merge insulin resistance,the rate of insulin resistance was about60.61%(40/66);19cases of abnormal blood fat, the incidence of dyslipidemia was28.79%(19/66). In PCOS group the levels serum visfatin was18.51±4.51ng/ml, higher than the control group in lipid levels of14.62±4.15ng/ml, with significantly statistical difference (p<0.01). Serum visfatin levels in obese PCOS group was20.89±2.89ng/ml, higher than the obese control group. The difference was statistically significant (p<0.01). Serum visfatin levels in non-obese PCOS group was13.03±1.44ng/ml and non obese control group within14.86±4.62ng/ml, there was no statistically significant difference (p>0.05).2. The clinical characteristics, serum visfatin levels in different PCOS group and correlation analysis.2.1According to the androgen level:visfatin,BMI,E2,HOMA-IR,TG levels are significantly higher in hyperandrogenism than unhyperandrogenism(p<0.01); HDL level is significantly lower in hyperandrogenism than unhyperandrogenism(p<0.01); LH/FSH, LH are higher in hyperandrogenism than unhyperandrogenism (p<0.05), the rest of the index difference has no significance in statistics (p>0.05)2.2According to the HOMA-IR:visfatin,BMI, T, HOMA IR, HDLwere higher in IR group than unIR group, the difference is statistically significant(p<0.01); LH/FSH, TG are higher in IR group than in unIR group, the differences are significant (p<0.05), the rest of the index difference has no significance in statistics (p>0.05).2.3According to the BMI:Visfatin, T, HOMA IR, TC, TG, LDL levels are higher in BMI>25group than BMI<25group, the difference is statistically significant(p<0.01); HDL was lower in BMI>25group han BMI<25group, the difference were statistically significant(p<0.01); Menstrual cycle was longer and E2was lower in BMI>25group han BMI<25group, the difference is statistically significant(p<0.05); the rest of the index difference has no significance in statistics (p>0.05)2.4According to dyslipidemia:BMI, T, HOMA IR, visfatin levels were higher in dyslipidemia group than in undyslipidemia group,the difference is statistically significant(p<0.01); LH, LH/FSH levels are higher in dyslipidemia group than in undyslipidemia group,the difference is statistically significant(p<0.05); the rest of the index difference has no significance in statistics (p>0.05)2.5Regression analysis:multiple linear regression analysis showed that BMI, LH/FSH, HDL (p<0.05) are the factors involved in serum lipid levels in.Conclusion:1. The serum level of visfatin is higher in PCOS group than in the control group,in the obese PCOS group than in the obese control group.It is satistically different. The serum level of visfatin has not significance in statistics in the non-obese PCOS group than in the non-obese control group it is estimated that the increase of visfatin is highly associated with the increase of fat of Internal organs.2. The level of visfatin in PCOS patients with different clinical phenotypes exists correlation:visfatin in PCOS patients have positively correlation with androgen, BMI, TG and HOMA-IR and have negatively correlated with HDL levels.3. Multiple regression analysis shows that BMI, LH/FSH and HDLare relevant factors of the level of serum visfatin.4. Visfatin is a new effective factor which can be used for evaluating glucolipid metabolic abnormalities and are expected to become effective on PCOS treatment.